Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and related high-grade B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Transformed B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-07